Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "CE"

9359 News Found

New England Biolabs unveils high-speed flu sequencing tool to bolster global outbreak surveillance
R&D | November 18, 2025

New England Biolabs unveils high-speed flu sequencing tool to bolster global outbreak surveillance

Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing


SPARC announces consolidation of R&D laboratories and facilities
R&D | November 17, 2025

SPARC announces consolidation of R&D laboratories and facilities

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations


Medico Remedies gets GMP compliance certificate from SMDC, Ukraine
News | November 16, 2025

Medico Remedies gets GMP compliance certificate from SMDC, Ukraine

SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)


ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
Biopharma | November 16, 2025

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies


Cenmed and Curavit team up to revolutionize clinical trial logistics
Supply Chain | November 16, 2025

Cenmed and Curavit team up to revolutionize clinical trial logistics

This collaboration turns kitting into a strategic advantage for sponsors and sites


Zydus receives final approval from USFDA for Leuprolide Acetate injection
Drug Approval | November 15, 2025

Zydus receives final approval from USFDA for Leuprolide Acetate injection

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer


Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
Drug Approval | November 14, 2025

Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis


Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Drug Approval | November 14, 2025

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor